ReviewTranslational lung cancer research2012

Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?

Lothar R Pilz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.